Finerenone improves doxorubicin-induced cardiotoxicity by inhibiting cardiomyocyte apoptosis through the TAK1-p38 axis
{{output}}
Although doxorubicin (DOX) is a potent chemotherapeutic agent, its clinical use is limited by dose-dependent cardiotoxicity. Doxorubicin-induced cardiotoxicity (DIC) promotes cardiomyocyte apoptosis, which leads to cardiac dysfunction, remodeling, and even hea... ...
